Abstract:CMR techniques are increasingly being used to evaluate myocardial extracellular volume (ECV). In the most commonly applied method, ECV is quantified using haematocrit-adjusted myocardial and blood T1 values measured before and after gadolinium bolus. The technique is based on a two-compartment model, which assumes contrast kinetic effects to be negligible due to a dynamic equilibrium between blood and myocardium (Dynamic-Equilibrium CMR; DynEq-CMR). This study assessed the effect of contrast dose, post-contrast acquisition time, myocardial regionality, cardiac cycle and gender on DynEq-CMR ECV measurement. 30 healthy volunteers (asymptomatic, no cardiovascular risk factors, normal examination and ECG) were prospectively split into 3 age and sex-matched groups (there were also no differences in mean eGFR, body surface area, heart rate, LV mass and volumetrics between groups): Group A received 0.10 mmol/kg Gd-DTPA, Group B 0.15 mmol/kg and Group C 0.20 mmol/kg. Mid-ventricular short-axis modified look locker inversion recovery (MOLLI) imaging was performed at 1.5T before, and at 2 min intervals between 2–20 min after, contrast administration, with same-day haematocrit measurement. MOLLI imaging was repeated in early systole (150 ms after R wave) pre- and at 10 min post-contrast. Resulting pixelwise T1 maps (figure 1; T1 maps at selected time-points are shown) were used to calculate ECV (Matlab). (Phantom studies performed prior to patient scanning determined T1 measurement accuracy and heart-rate correction algorithm). Figure 1 Pre-contrast myocardial (A 1051±49 ms; B 1045±49 ms; C 1040±43 ms; p=0.87) and blood (A 1678±98 ms; B 1645±118 ms; C 1686±101 ms; p=0.66) T1 times did not differ significantly between groups. Mean myocardial (A 542±65 ms; B 465±69 ms; C 407±55 ms; p<0.001) and blood (A 407±73 ms; B 307±67 ms; C 252±48 ms; p<0.001) T1 averaged over all time points post-contrast shortened significantly as contrast dose increased (figure 2). Mean ECV was significantly higher in group A compared to groups B and C (A 27.7±3.7%; B 25.8±3.4%; C 25.8±2.8%; p<0.001). The difference between groups B and C was not significant. ECV increased linearly over time in each group; between 2 and 20 min post-contrast, ECV increased from 27.2±2.7% to 28.8±3.4%, p=0.020 in group A; 25.3±2.8% to 26.5±3.2%, p=0.004 in group B; and 25.2±1.7% to 26.2±2.1%, p=0.068 in group C. ECV varied significantly between myocardial regions, being highest in the septum and lowest in the lateral wall in each group. ECV did not differ significantly between diastole and systole. ECV was significantly higher in females in each group (A female 29.6±3.0%, male 25.4±3.0%, p<0.001; B female 27.4±2.7%, male 23.6±2.9%, p<0.001; C female 26.1±2.8%, male 24.7±2.5%, p=0.027). Figure 2 The small increase in ECV over time suggests that an incomplete dynamic equilibrium between blood and myocardium is achieved. DynEq-CMR-derived ECV varies according to contrast dose, myocardial region and gender.

Is a timely assessment of the hematocrit necessary for cardiovascular magnetic resonance–derived extracellular volume measurements?

A comparative study of synthetic and venous hematocrit for calculating cardiovascular magnetic resonance-derived extracellular volume

Synthetic Extracellular Volume in Cardiac Magnetic Resonance Without Blood Sampling: a Reliable Tool to Replace Conventional Extracellular Volume

Synthetic hematocrit from virtual non-contrast images for myocardial extracellular volume evaluation with photon-counting detector CT

Quantification of myocardial extracellular volume without blood sampling

Synthetic extracellular volume fraction without hematocrit sampling for hepatic applications

Performance of Synthetic Extracellular Volume Fraction in Different Cardiac Phenotypes From a Prospective Cohort of Patients Referred for Cardiac Magnetic Resonance

Establishment and validation of an extracellular volume model without blood sampling in ST-segment elevation myocardial infarction patients

Improvement of Quantification of Myocardial Synthetic ECV with Second-Generation Deep Learning Reconstruction

Blood T1* correction increases accuracy of extracellular volume measurements using 3T cardiovascular magnetic resonance: Comparison of T1 and T1* maps

Interstitial Myocardial Fibrosis Assessed As Extracellular Volume Fraction with Low-Radiation-dose Cardiac CT.

Iodine-based extracellular volume for evaluating myocardial status in patients undergoing percutaneous coronary intervention for acute myocardial infarction by using dual-layer spectral detector computed tomography: a comparison study with magnetic resonance

Reply: Prediction of the Left Ventricular Functional Outcome by Myocardial Extracellular Volume Fraction Measured Using Magnetic Resonance Imaging; Methodological Issue

Myocardial Extracellular Volume Derived from Contrast-Enhanced Chest Computed Tomography for Longitudinal Evaluation of Cardiotoxicity in Patients with Breast Cancer Treated with Anthracyclines

084 EFFECT OF CONTRAST DOSE, POST-CONTRAST ACQUISITION TIME, MYOCARDIAL REGIONALITY, CARDIAC CYCLE AND GENDER ON DYNAMIC-EQUILIBRIUM CONTRAST CMR MEASUREMENT OF MYOCARDIAL EXTRACELLULAR VOLUME

Role of Myocardial Extracellular Volume Fraction Measured with Magnetic Resonance Imaging in the Prediction of Left Ventricular Functional Outcome after Revascularization of Chronic Total Occlusion of Coronary Arteries

Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy

Quantitation of Diffuse Myocardial Fibrosis Using Cardiac CT in Heart Failure: a Pilot Study

Myocardial extracellular volume quantification with computed tomography—current status and future outlook

Optimal Threshold for the Diagnosis of Anemia Severity on Unenhanced Thoracic CT: A Preliminary Study

Myocardial extracellular volume fraction quantitation using cardiac dual-energy CT with late iodine enhancement in patients with heart failure without coronary artery disease: A single-center prospective study